PHORA is a first in class risk stratification tool for pulmonary arterial hypertension (PAH)
- Intuitive user interface for physicians
- Integration with existing EHR system
- Mobile utility
- Machine learning derived algorithm from top clinical trials
Model in development, demo coming soon.
- To provide prognostic tool for physicians to stratify PAH patients
- To capitalize on advanced computer learning and data mining technology
- To assist the clinical team with managing workflow
- To inform need for additional diagnostics and referral to advanced PH center of excellence
This project is to develop a multi-platform clinical decision support system (CDSS) in pulmonary arterial hypertension (PAH) for physicians, PHORA (Pulmonary Hypertension Outcomes Risk Assessment), which can be used to: (a) guide therapeutic decisions and (b) optimize clinical trial design. We will use clinical trial data from several large databases of completed trials in PAH, an ongoing PAH registry (REVEAL) to derive the predictive models for the CDSS. The team behind is effort compromises a multi-disciplinary group of specialties including: biomedical engineering, advanced PAH physicians, computer science (machine learning/data mining), human computer interaction, and allied health care experts. Our intention is to engage all stakeholders in the PAH workflow to achieve consensus and integrate PHORA into practice. Successful completion of this project will lay the foundation for a prospective, multi-center trial to evaluate PHORA for long-term patient outcomes. The ultimate aim is to disseminate this resource to improve the efficiency, efficacy, and cost-effectiveness of treatment for PAH.
PHORA is the result of a global endeavor with participation from Actelion, Bayer, FDA, United Therapeutics, NHLBI and PHA.